Cancer Gene Therapy Market Benefits, Opportunities and Future Investments Forecast To 2024

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade.

Delaware, Selbyville - June 13, 2019 /MarketersMedia/ —

Cancer Gene Therapy Market size is expected to exceed USD 4.3 billion by 2024; as per a new research report by Global Market Insights, Inc.

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade. This alarming increase in number of patients necessitates this as a potential treatment approach addressing the growing global burden of the disease.

Retroviral vector-mediated gene transfer dominated the development by enabling the conversion of single stranded RNA into a double stranded DNA molecule, which steadily integrates into the target cell genome. These vectors are used to permanently modify the host cell nuclear genome and will register a robust growth of over 20%.

Request a sample of this premium report titled at https://www.marketstudyreport.com/request-a-sample/467801/?utm_source=MM-VHS

Growing number of clinical trials and availability of wide range of genes and vectors used in these trials will enable emergence of new treatment modalities to help make cancer a manageable disease. By the end of 2012, the number of clinical trials crossed 1,800 worldwide.

Adenoviral vector remains as the most common oncology application due to its competent nuclear mechanism and low pathogenicity. It is widely used in replacement approaches, suicide and gene-based immunotherapy, and syndicate with chemotherapy and is anticipated to grow at 20% CAGR.

Increased adoption of emerging genomic technologies such as NGS and high density micro array coupled with favorable government initiatives will fuel global cancer gene therapy market size. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance. However, high cost of development lack of reimbursement and regulatory processes will restrain industry growth.

U.S. led the industry owing to increased R&D funding and other government initiatives. Growing number of biotech companies are engaging in R&D and clinical trials of gene therapy products. Increased demand for DNA vaccines and increasing interest of venture capitalists to invest in commercialization of gene therapies will trigger industry expansion.

China cancer gene therapy market size attributed to over 35% APAC revenue in 2015. With the launch of Gendicine and increasing healthcare expenditure and robust R&D facilities will enable industry growth.

Key insights from the report include:

U.S. cancer gene therapy market share accounted for over 95% regional revenue in 2015, with market size of USD 235 million and a forecast to grow at 20.9% CAGR.

Request a discount on standard prices of this premium report titled at https://www.marketstudyreport.com/check-for-discount/467801/?utm_source=MM-VHS

UK was over USD 92.0 million in 2015, and will grow at 20.8% CAGR owing to increasing incidence of cancer and adoption of advanced treatment methods.
China market size was valued at USD 99.6 million in 2015 and growth expectations of 21% CAGR over the forecast years.

Key players include SiBiono, Altor Bioscience Corporation, Shanghai Sunway Biotech company limited, Amgen, BioCancell, OncoGeneX, Aduro Biotech, GlobeImmune, Inc., New Link Genetics., ZioPharm Oncology, MolMed, GENELUX, Gradalis, MultiVir.
The industry is highly fragmented and is dominated by several small biotech firms collectively accounting for over 80% of cancer gene therapy market pipeline. Major growth strategies adopted by these small firms include, technology transfer, licensing and commercialization deals, strategic collaborations and mergers and acquisitions to retain their industry position.

Report Content
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.1.1. Initial data exploration
1.1.2. Statistical modeling and forecast
1.1.3. Industry insights and validation
1.1.4. Research scope & assumptions
1.2. Data Sources
Chapter 2. Executive Summary
2.1. Cancer genetics industry 360 degree synopsis, 2012 - 2024
2.1.1. Business trends
2.1.2. Regional trends
2.1.3. Application trends
Chapter 3. Cancer Gene Therapy Industry Insights
3.1. Industry segmentation
3.2. IIndustry Size and forecast, 2012 - 2024
3.3. Industry Impact forces
3.3.1. Growth drivers
3.3.1.1. Technological advancements
3.3.1.2. Increased adoption of nanotechnology
3.3.1.3. Favorable government regulations
3.3.2. Industry pitfalls & challenges
3.3.2.1. High cost of cancer genetherapy
3.4. Growth potential analysis
3.5. Porter's analysis
3.6. Key opportunities prioritized, 2015
3.7. PESTEL analysis
3.8. Regulatory Landscape
3.8.1. U.S.
3.8.2. EU
3.8.3. China
3.9. Scientific and Ethical issues in Gene Therapy
3.10. Competitive landscape, 2015
3.11. Pipeline Analysis by cancer type
3.11.1. Head and Neck Cancer Pipeline Analysis
3.11.2. Breast Cancer Pipeline Analysis
3.11.3. Gastro Intestinal Cancer Pipeline Analysis
3.11.4. Gentiourinary Cancer Pipeline Analysis
3.11.5. Gynecological Cancer Pipeline Analysis
3.11.6. Haemotological Cancer Pipeline Analysis
3.11.7. Neurologic Cancer Pipeline Analysis
3.11.8. Respiratory Cancer Pipeline Analysis
3.11.9. Skin Cancer Pipeline Analysis
Chapter 4. Cancer Gene Therapy Insights
4.1. Cancer gene therapy market share by therapy, 2015 & 2024
4.2. Gene Induced Immunotherapy
4.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.2.2. Delivery of cytokine gene
4.2.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.2.3. Delivery of tumor antigen gene
4.2.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3. Oncolytic Virotherapy
4.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.2. Adenoviruses
4.3.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.3. Lentiviruses
4.3.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.4. Retrovirus
4.3.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.5. Adeno Associated Virus
4.3.5.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.6. Herpes Simplex Virus
4.3.6.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.7. Alphavirus
4.3.7.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.8. Vaccinia Virus
4.3.8.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.9. Simian Virus
4.3.9.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.10. Others
4.3.10.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4. Gene transfer/ Gene replacement
4.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.2. Naked/Plasmid Vectors
4.4.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.3. Electroporation
4.4.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.4. Sonoportion
4.4.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.5. Magnetofection
4.4.5.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.6. Gene Gun
4.4.6.1. Market estimates and forecast, 2012-2024 (USD Million)

Complete report titled at https://www.marketstudyreport.com/reports/cancer-gene-therapy-market

About Us:

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Info:
Name: Arun Hegde
Email: Send Email
Organization: Market Study Report
Address: 4 North Main Street, Selbyville, Delaware 19975 USA
Phone: 1-302-273-0910
Website: https://www.marketstudyreport.com/

Source URL: https://marketersmedia.com/cancer-gene-therapy-market-benefits-opportunities-and-future-investments-forecast-to-2024/524003

Source: MarketersMedia

Release ID: 524003

More News From thebudgetreport.com

Nancy Pelosi unveils an ambitious plan to lower drug prices

Sep 20, 2019

WASHINGTON — Putting her stamp on the health care issue that worries consumers the most, House Speaker Nancy Pelosi on Thursday unveiled an ambitious plan to lower drug prices for seniors on Medicare and younger people with private insurance. Pelosi, D-Calif., would empower Medicare to negotiate prices for up to 250 of the costliest drugs, including insulin. Pharmaceutical companies that refuse to negotiate could face steep penalties. Additionally, drugmakers that hike prices beyond inflation would have to pay rebates to Medicare. The plan would limit copays for seniors covered by Medicare's "Part D" prescription drug program to $2,000. And Medicare-negotiated...

Mortgage rates boosted US home sales 1.3% in August

Sep 20, 2019

WASHINGTON — U.S. home sales rose 1.3% in August to the highest level in 17 months, as mortgage rates near historic lows have spurred a rush of home-buying. The National Association of Realtors said Thursday that homes sold last month at a seasonally adjusted annualized rate of 5.49 million units, the best performance since March 2018. Sales have increased 2.6% from a year ago. Cheaper borrowing costs have increased affordability for buyers, but they have also led to higher prices amid a shortage of properties for sale. The median sales price climbed 4.7% from a year ago to $278,200, outpacing...

Japan central bank stands pat after Fed rate cut

Sep 20, 2019

TOKYO — Japan's central bank opted Thursday to keep its monetary policy unchanged despite the growing signs of trouble that prompted the Federal Reserve to cut its benchmark rate. The Bank of Japan said in its policy statement that exports, industrial output and business sentiment had been affected by the slowdown in overseas markets. The China-U.S. tariff war has pummeled Japan's exports. But the BOJ said strong corporate profits were supporting business investment. The Federal Reserve reduced its key short-term rate — which influences many consumer and business loans — by a quarter-point to a range of 1.75%-2% on Wednesday....

Trump bars California from setting stricter fuel standards

Sep 20, 2019

WASHINGTON — President Donald Trump announced Wednesday that his administration is revoking California's authority to set auto mileage standards stricter than those issued by federal regulators, a move critics said would result in less fuel efficient cars that create more planet-warming pollution. In a tweet, Trump said his action would result in less expensive, safer cars. He also predicted Americans would purchase more new cars, which would result in cleaner air as older models are taken off the roads. "Many more cars will be produced under the new and uniform standard, meaning significantly more JOBS, JOBS, JOBS! Automakers should seize...

Oil price drops on hopes for quick recovery of Saudi output

Sep 20, 2019

LONDON — The price of oil is falling back further after the Saudi government said half of production that was knocked out by an attack over the weekend had already had been restored. Benchmark U.S. crude was down 42 cents to $58.92 per barrel in electronic trading Wednesday. The contract fell $3.56 on Tuesday. Brent crude, the international benchmark, fell 27 cents to $64.28 per barrel in London, having dropped $4.47 the previous session. The attack on oil producer Saudi Aramco's processing facility in Abqaiq saw crude surge more than 14% on Monday, about as much as it did when...

The Budget Report seeks to provide comprehensive coverage and analysis on the current economic, financial issues around the world. First hand finance and economic news all day, every day.